

FORMS RELATING TO LISTING

FORM F

The Growth Enterprise Market (GEM)

Company Information Sheet

The Stock Exchange of Hong Kong Limited takes no responsibility for the contents of this information sheet, makes no representation as to its accuracy or completeness and expressly disclaims any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this information sheet.

Company name : Sino Biopharmaceutical Limited

Stock code (ordinary shares) : 8027

This information sheet contains certain particulars concerning the above company (the “Company”) which is listed on the Growth Enterprise Market (“GEM”) of The Stock Exchange of Hong Kong Limited (the “Exchange”). These particulars are provided for the purpose of giving information to the public with regard to the Company in compliance with the Rules Governing the Listing of Securities on the Growth Enterprise Market of The Stock Exchange of Hong Kong Limited (the “GEM Listing Rules”). They will be displayed at the GEM website on the Internet. This information sheet does not purport to be a complete summary of information relevant to the Company and/or its securities.

The information in this sheet was updated as of 23 April, 2003

A. General

Place of Incorporation : Cayman Islands

Date of initial listing of GEM : 29 September, 2000

Name of Sponsor : DBS Asia Capital Limited

Names of Directors : ***Executive Directors***
Mr. Tse Ping
Mr. Tao Huiqi
Mr. Wang Jinyu

Non-executive Directors
Ms. Josephine Price

Independent non-executive Directors
Ms. Peng Yu
Mr. Hu Xi Ming

| Names of substantial shareholders (as such term is defined in rule 1.01 of the GEM Listing Rules) and their respective interests in the ordinary shares and other securities of the Company | : | Number of Shares or attributable number of Shares held immediately after the Placing | Approximate percentage of shareholding or attributable percentage of shareholding immediately after the Placing |
|--|---|---|--|
| Name | | | |
| Mr. Tse Ping <i>(Note 1)</i> | | 234,120,000 | 70.52 |
| Conspicuous Group Limited | | 108,000,000 | 32.53 |
| Remarkable Industries Limited | | 57,317,760 | 17.29 |
| Validated Profits Limited | | 65,802,240 | 19.82 |

Notes:

- (1) Interest attributable to Mr. Tse Ping comprised of: (i) personal interest of 3,000,000 shares; and (ii) 231,120,000 shares attributable to Mr. Tse Ping in the Company, which are held through Conspicuous Group Limited, Remarkable Industries Limited and Validated Profits Limited. Each of Conspicuous Group Limited, Remarkable Industries Limited and Validated Profits Limited is an investment holding company wholly owned by Mr. Tse Ping who is an executive Director.

| | | |
|--|---|---|
| Name of company(ies) listed on GEM or the Main Board of the Stock Exchange within the same group as the Company | : | N/A |
| Financial year end date | : | 31 December |
| Registered address | : | Code Trust Company (Cayman) Limited Century Yard Cricket Square Hutchins Drive P.O. Box 2681GT George Town Grand Cayman British West Indies |

| | |
|--|--|
| Head office and principal place of business in Hong Kong | : Unit 09, 41st Floor, Office Tower Convention Plaza 1 Harbour Road Wanchai Hong Kong |
| Web-site address | : www.sinobiopharm.com |
| Share registrars | : <i>Principal share registrar and transfer office:</i> Bank of Butterfield International (Cayman) Ltd. P.O. Box 705 Butterfield House Fort Street George Town Grand Town Cayman Islands <i>Hong Kong branch share registrar and transfer office:</i> Tengis Limited G/F., Bank of East Asia Harbour View Centre 56 Gloucester Road Wanchai Hong Kong |
| Auditors | : Ernst & Young <i>Certified Public Accountants</i> 15th Floor, Hutchison House 10 Harcourt Road Central Hong Kong |

B. Business activities

The Group is principally engaged in the research and development, production and sale of (i) a series of biopharmaceutical products for the medical treatment of ophthalmia and (ii) a series of modernised Chinese medicines and chemical medicines for the medical treatment of hepatitis in the People's Republic of China.

C. Ordinary shares

| | |
|--|----------------------|
| Number of ordinary shares in issue | : 332,000,000 Shares |
| Par value of ordinary shares in issue | : HK\$0.10 |
| Board lot size (in number of shares) | : 2,000 |
| Name of other stock exchange(s) on which ordinary shares are also listed | : N/A |

D. Warrants

| | | |
|--|---|-----|
| Stock code | : | N/A |
| Board lot size | : | N/A |
| Expiry date | : | N/A |
| Exercise price | : | N/A |
| Conversion ratio (Not applicable if the warrant is denominated in dollar value of conversion right) | : | N/A |
| No. of warrants outstanding | : | N/A |
| No. of shares falling to be issued upon the exercise of outstanding warrants | : | N/A |

E. Other securities

Share Option

| | | |
|--------------------------------------|---|-----------------|
| Date of options granted | : | 2 January, 2001 |
| No. of Shares subject to the options | : | 18,000,000 |
| Exercise price per share | : | HK\$0.74 |

Convertible bonds

| | | |
|---|---|------------------|
| (1) Date of issue of the convertible bonds | : | 22 October, 2002 |
| Principal amount | : | US\$6,000,000 |
| Conversion price | : | HK\$2.85 |
| (2) Date of issue of convertible bonds | : | 31 March, 2003 |
| Principal amount | : | US\$4,000,000 |
| Conversion price | : | HK\$2.85 |

RESPONSIBILITY STATEMENT

The directors of the Company (the “Directors”) as at the date hereof hereby collectively and individually accept full responsibility for the accuracy of the information contained in this information sheet (the “Information”) and confirm, having made all reasonable inquiries, that to the best of their knowledge and belief the Information is accurate and complete in all material respects and not misleading and that there are no other matters the omission of which would make any Information inaccurate or misleading.

The Directors also collectively and individually accept full responsibility for submitting a revised information sheet, as soon as reasonably practicable after any particulars on the form previously published cease to be accurate.

The Directors acknowledge that the Exchange has no responsibility whatsoever with regard to the Information and undertake to indemnify the Exchange against all liability incurred and all losses suffered by the Exchange in connection with or relating to the Information.

Signed:

Tse Ping

Wang Jinyu

Tao Huiqi

Peng Yu

Josephine Price

Hu Xi Ming